Top

Published in:

Open Access 01-12-2012 | Research article

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

Published in: BMC Urology | Issue 1/2012

Abstract

Background

To clarify the significant clinicopathological and postdosimetric parameters to predict PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.

Methods

We studied 200 consecutive patients who received LDR-brachytherapy between July 2004 and November 2008. Of them, 137 patients did not receive neoadjuvant or adjuvant androgen deprivation therapy. One hundred and forty-two patients were treated with LDR-brachytherapy alone, and 58 were treated with LDR-brachytherapy in combination with external beam radiation therapy. The cut-off value of PSA bounce was 0.1 ng/mL. The incidence, time, height, and duration of PSA bounce were investigated. Clinicopathological and postdosimetric parameters were evaluated to elucidate independent factors to predict PSA bounce in hormone-naïve patients who underwent LDR-brachytherapy alone.

Results

Fifty patients (25%) showed PSA bounce and 10 patients (5%) showed PSA failure. The median time, height, and duration of PSA bounce were 17 months, 0.29 ng/mL, and 7.0 months, respectively. In 103 hormone-naïve patients treated with LDR-brachytherapy alone, and univariate Cox proportional regression hazard model indicated that age and minimal percentage of the dose received by 30% and 90% of the urethra were independent predictors of PSA bounce. With a multivariate Cox proportional regression hazard model, minimal percentage of the dose received by 90% of the urethra was the most significant parameter of PSA bounce.

Conclusions

Minimal percentage of the dose received by 90% of the urethra was the most significant predictor of PSA bounce in hormone-naïve patients treated with LDR-brachytherapy alone.

Available only for authorised users

Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000, 163 (4): 1085-1089. 10.1016/S0022-5347(05)67698-7.CrossRefPubMed

Das P, Chen MH, Valentine K, Lopes L, Cormack RA, Renshaw AA, Tempany CM, Kumar S, D'Amico AV: Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys. 2002, 54 (3): 698-702. 10.1016/S0360-3016(02)03036-5.CrossRefPubMed

Stock RG, Stone NN, Cesaretti JA: Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003, 56 (2): 448-453. 10.1016/S0360-3016(02)04470-X.CrossRefPubMed

Critz FA, Williams WH, Levinson AK, Benton JB, Schnell FJ, Holladay CT, Shrake PD: Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol. 2003, 170 (5): 1864-1867. 10.1097/01.ju.0000091644.41330.2a.CrossRefPubMed

Toledano A, Chauveinc L, Flam T, Thiounn N, Solignac S, Timbert M, Rosenwald JC, Cosset JM: PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. Brachytherapy. 2006, 5 (2): 122-126. 10.1016/j.brachy.2006.02.003.CrossRefPubMed

Bostancic C, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath R, Lief J, Gutman SE: Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007, 68 (5): 1431-1437. 10.1016/j.ijrobp.2007.01.066.CrossRefPubMed

Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G: PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007, 69 (2): 426-433. 10.1016/j.ijrobp.2007.03.031.CrossRefPubMed

Satoh T, Ishiyama H, Matsumoto K, Tsumura H, Kitano M, Hayakawa K, Ebara S, Nasu Y, Kumon H, Kanazawa S, Miki K, Egawa S, Aoki M, Toya K, Yorozu A, Nagata H, Saito S, Baba S: Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int. 2009, 103 (8): 1064-1068. 10.1111/j.1464-410X.2008.08234.x.CrossRefPubMed

Kanai K, Nakashima J, Sugawara A, Shigematsu N, Nagata H, Kikuchi E, Miyajima A, Nakagawa K, Kubo A, Oya M: Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. Int J Clin Oncol. 2009, 14 (6): 502-506. 10.1007/s10147-009-0909-0.CrossRefPubMed

10.

McGrath SD, Antonucci JV, Fitch DL, Ghilezan M, Gustafson GS, Vicini FA, Martinez AA, Kestin LL: PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy. 2010, 9 (2): 137-144. 10.1016/j.brachy.2009.07.005.CrossRefPubMed

11.

Tanaka N, Asakawa I, Kondo H, Tanaka M, Fujimoto K, Hasegawa M, Konishi N, Hirao Y: Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients. Int J Urol. 2009, 16 (1): 70-74. 10.1111/j.1442-2042.2008.02172.x.CrossRefPubMed

12.

Stock RG, Stone NN, Cesaretti JA, Rosenstein BS: Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006, 64 (2): 527-533. 10.1016/j.ijrobp.2005.07.981.CrossRefPubMed

13.

Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006, 65 (4): 965-974. 10.1016/j.ijrobp.2006.04.029.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/12/28/prepub

Title: Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
Publication date: 01-12-2012
Published in: BMC Urology / Issue 1/2012
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/1471-2490-12-28

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer

Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder

Appropriate use of indwelling urethra catheters in hospitalized patients: results of a multicentre prevalence study

Urinary levels of Hepatocarcinoma-intestine-pancreas/Pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer

Oral zinc supplementation restore high molecular weight seminal zinc binding protein to normal value in Iraqi infertile men

Resistance profiles of urinary tract infections in general practice - an observational study